39.45
2.20%
-0.51
Avidity Biosciences Inc stock is currently priced at $39.45, with a 24-hour trading volume of 1.56M.
It has seen a -2.20% decreased in the last 24 hours and a +35.18% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $39.14 pivot point. If it approaches the $41.22 resistance level, significant changes may occur.
Previous Close:
$39.96
Open:
$39.95
24h Volume:
1.56M
Market Cap:
$3.82B
Revenue:
$9.56M
Net Income/Loss:
$-212.22M
P/E Ratio:
-12.73
EPS:
-3.1
Net Cash Flow:
$-123.29M
1W Performance:
+46.92%
1M Performance:
+35.18%
6M Performance:
+386.67%
1Y Performance:
+220.59%
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858 401 7900
Address
10975 North Torrey Pines Road, Suite 150, La Jolla, CA
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
Jul-12-22 | Initiated | Raymond James | Strong Buy |
Sep-07-21 | Initiated | Evercore ISI | Outperform |
Jun-17-21 | Initiated | Needham | Buy |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Jul-07-20 | Initiated | Cowen | Outperform |
Jul-07-20 | Initiated | Credit Suisse | Outperform |
Jul-07-20 | Initiated | SVB Leerink | Outperform |
Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences to Participate in Upcoming Investor Conference - StockTitan
StockTitan
RNA Stock Sees Surge of Approximately 53.46% in Last Five Days – Knox Daily - Knox Daily
Knox Daily
Chart of the Day: Avidity Biosciences --- Something's Up??? - TradingView
TradingView
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday By Benzinga - Investing.com UK
Investing.com UK
Avidity Biosciences (NASDAQ:RNA) Trading 4.2% Higher on Analyst Upgrade - Defense World
Defense World
Avidity Biosciences (NASDAQ:RNA) Stock Price Up 4.2% After Analyst Upgrade - MarketBeat
MarketBeat
Avidity Biosciences Inc Stock (RNA) Financials Data
Avidity Biosciences Inc (RNA) Revenue 2024
RNA reported a revenue (TTM) of $9.56 million for the quarter ending December 31, 2023, a +3.64% rise year-over-year.
Avidity Biosciences Inc (RNA) Net Income 2024
RNA net income (TTM) was -$212.22 million for the quarter ending December 31, 2023, a -21.97% decrease year-over-year.
Avidity Biosciences Inc (RNA) Cash Flow 2024
RNA recorded a free cash flow (TTM) of -$123.29 million for the quarter ending December 31, 2023, a +11.36% increase year-over-year.
Avidity Biosciences Inc (RNA) Earnings per Share 2024
RNA earnings per share (TTM) was -$2.91 for the quarter ending December 31, 2023, a +12.61% growth year-over-year.
Avidity Biosciences Inc Stock (RNA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Boyce Sarah | President and CEO |
Jun 04 '24 |
Sale |
27.42 |
28,000 |
767,780 |
112,117 |
LEVIN ARTHUR A | Director |
May 20 '24 |
Option Exercise |
1.24 |
5,000 |
6,200 |
19,830 |
LEVIN ARTHUR A | Director |
May 20 '24 |
Sale |
29.90 |
5,000 |
149,481 |
14,830 |
MacLean Michael F | Chief Financial Officer |
May 14 '24 |
Option Exercise |
8.82 |
75,000 |
661,500 |
119,093 |
MacLean Michael F | Chief Financial Officer |
May 14 '24 |
Sale |
28.28 |
75,000 |
2,121,045 |
44,093 |
Boyce Sarah | President and CEO |
May 07 '24 |
Option Exercise |
1.24 |
28,000 |
34,720 |
140,117 |
Boyce Sarah | President and CEO |
May 07 '24 |
Sale |
25.54 |
28,000 |
715,050 |
112,117 |
LEVIN ARTHUR A | Director |
Apr 19 '24 |
Option Exercise |
1.24 |
5,000 |
6,200 |
19,830 |
LEVIN ARTHUR A | Director |
Apr 19 '24 |
Sale |
22.82 |
5,000 |
114,123 |
14,830 |
LEVIN ARTHUR A | Director |
Apr 03 '24 |
Sale |
27.11 |
20,000 |
542,214 |
253,872 |
About Avidity Biosciences Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.
Cap:
|
Volume (24h):